Vildagliptin, Sitagliptin Have Similar Effects on Incretin
Inter-individual variability seen in L-cell feedback induced by DPP-4 inhibitors
MONDAY, June 20, 2016 (HealthDay News) -- The dipeptidyl peptidase-4 (DPP-4) inhibitors vildagliptin and sitagliptin have similar effects on incretin hormone secretion, according to a study published online June 14 in Diabetes, Obesity and Metabolism.
Oleg Baranov, from the Diabeteszentrum Bad Lauterberg in Germany, and colleagues compared the clinical effects of vildagliptin and sitagliptin in 24 patients with type 2 diabetes (12 diet/exercise, 12 on metformin). Participants were treated in randomized order for seven to nine days with vildagliptin, sitagliptin, or placebo.
The researchers found that with vildagliptin and sitagliptin, intact glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide concentrations were doubled. In most patients, meal-related total GLP-1 responses were reduced by vildagliptin and sitagliptin treatment (P = 0.0005 and 0.019, respectively), with considerable inter-individual variation. In those with greater increases in intact GLP-1 relative to total GLP-1 and who had greater reductions in fasting plasma glucose after DPP-4 inhibition, L-cell feedback was more pronounced. Overall, K-cell feedback inhibition was not significant. No between-group differences were seen in any clinical parameters.
"Vildagliptin and sitagliptin affected incretin hormones, glucose concentrations, insulin, and glucagon secretion in a similar manner," the authors write. "Inter-individual variations in L-cell feedback inhibition may indicate heterogeneity in the clinical response to DPP-4 inhibition."
Several authors disclosed financial ties to pharmaceutical companies, including Novartis Pharma, which manufactures vildagliptin and funded the study.